title: Epidermal growth factor receptor inhibition with erlotinib ameliorates anti-Thy 1.1-induced experimental glomerulonephritis.
abstract: Mesangial proliferative glomerulonephritis is a common glomerular disorder that may lead to end-stage renal disease. Epidermal growth factor (EGF) plays an important role in the regulation of cell growth, proliferation, and differentiation and in the pathology of various renal diseases. Erlotinib is a novel, oral, highly selective tyrosine kinase inhibitor of the EGF receptor. It is clinically used to treat non-small cell lung and pancreatic cancers. Here, we investigated the effect of erlotinib on the progression of mesangioproliferative glomerulonephritis in an experimental model.
  
  
  
  Mesangial glomerulonephritis was induced with anti-rat Thy-1.1 antibody in male Wistar rats weighing 150-160 g. Rats were treated with erlotinib (10 mg/kg/day p.o.) or vehicle only (polyethylene glycol). Native Wistar rat kidneys were used as histological controls. Serum creatinine levels were measured at day 7. Kidneys were harvested 7 days after antibody administration for histology.
  
  
  
  Native controls showed no histological signs of glomerular pathology. In the vehicle group, intense glomerular inflammation developed after 7 days and prominent mesangial cell proliferation and glomerular matrix accumulation was seen. Erlotinib was well tolerated and there were no adverse effects during the follow-up period. Erlotinib significantly prevented progression of the glomerular inflammatory response and glomerular mesangial cell proliferation as well as matrix accumulation when compared with the vehicle group. Erlotinib also preserved renal function.
  
  
  
  These results indicate that erlotinib prevents the early events of experimental mesangial proliferative glomerulonephritis. Therefore, inhibition of the EGF receptor with erlotinib could prevent the progression of glomerulonephritis also in clinical nephrology.
authors.affiliation: Transplantation Laboratory, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland. jukka.m.rintala@helsinki.fi.
authors.forename: Jukka M
authors.initials: JM
authors.lastname: Rintala
authors.affiliation: Transplantation Laboratory, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland.|Transplantation and Liver Surgery Unit, Helsinki University Hospital, Helsinki, Finland.
authors.forename: Johanna
authors.initials: J
authors.lastname: Savikko
authors.affiliation: Transplantation Laboratory, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland.
authors.forename: Sini E
authors.initials: SE
authors.lastname: Rintala
authors.affiliation: Transplantation Laboratory, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland.
authors.forename: Niina
authors.initials: N
authors.lastname: Palin
authors.affiliation: Transplantation Laboratory, University of Helsinki, P.O. Box 21, Haartmaninkatu 3, 00014, Helsinki, Finland.|Division of Nephrology, Department of Medicine, Helsinki University Hospital, Helsinki, Finland.
authors.forename: Petri K
authors.initials: PK
authors.lastname: Koskinen
mesh_terms: D000818:Animals; D003404:Creatinine / Q000097:blood; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride / Q000494:pharmacology*; D005921:Glomerulonephritis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007518:Isoantibodies / Q000494:pharmacology*; D007668:Kidney / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar
chemical_list: D007518:Isoantibodies; C035678:anti-Thy antibody; D003404:Creatinine; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors
keywords: Epidermal growth factor; Erlotinib; Experimental glomerulonephritis